Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Archive ouverte | Benotmane, Ilies | CCSD

The cilgavimab-tixagevimab combination retains a partial in vitro neutralizing activity against the current SARS-CoV-2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we examined whether preexposure prophylaxis with ci...

In-depth virological assessment of kidney transplant recipients with COVID-19

Archive ouverte | Benotmane, Ilies | CCSD

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Archive ouverte | Benotmane, Ilies | CCSD